Ionis Pharmaceuticals vs Pacira BioSciences
IONS and PCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IONS and PCRX compare
Ionis Pharmaceuticals is the larger company, worth 3.1 times as much as Pacira BioSciences ($4.5B against $1.5B).
Pacira BioSciences grew revenue faster over the last twelve months (5.7% versus −7.4% for Ionis Pharmaceuticals).
Pacira BioSciences keeps more of each dollar of sales as profit, with a net margin of 2.0% compared with −64.7% at Ionis Pharmaceuticals.
Pacira BioSciences scores higher on the StockData Score (6 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IONS | PCRX |
|---|---|---|
| Size and price | ||
| Market cap | $4.5B | $1.5B |
| Share price | $26.96 | $36.48 |
| Change, 1 year | −62.3% | 53.4% |
| Change, 5 years | −7.2% | −29.3% |
| Beta (5Y) | 0.60 | 0.12 |
| Employees | 1,402 | 829 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 104× |
| P/S | 5.1× | 1.9× (better) |
| P/B | 10.2× | 2.2× (better) |
| EV/EBITDA | – | 14.9× |
| P/FCF | – | 8.1× |
| FCF yield | −12.5% | 12.3% (better) |
| Fair value | $27.86 | $28.47 |
| Margin of safety | 3.2% (better) | −28.1% |
| Growth | ||
| Revenue growth (TTM) | −7.4% | 5.7% (better) |
| Revenue growth, 5Y average | 5.3% | 11.1% (better) |
| EPS growth, 5Y average | – | −45.5% |
| Profitability | ||
| Gross margin | 98.2% (better) | 79.2% |
| Operating margin | −68.0% | 2.7% (better) |
| Net margin | −64.7% | 2.0% (better) |
| FCF margin | −64.2% | 24.1% (better) |
| Return on equity | −105% | 2.0% (better) |
| Return on invested capital | – | 3.0% |
| Financial health | ||
| Debt / equity | – | 0.54 |
| Net debt / EBITDA | – | 1.07 |
| Interest coverage | −31.6× | 1.3× (better) |
| Current ratio | 7.89 (better) | 5.04 |
| Altman Z-score | 0.23 | 2.44 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 10.2% |
| Shareholder yield | 0.00% | 10.2% (better) |
| Ownership | ||
| Held by institutions | 108% | 110% |
| Held by insiders | 0.81% | 6.1% |
| Insider net buying, 12 months | −$114M | −$2.4M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 12.8% | 8.9% |
Go deeper
- IONS stock overview
- IONS income statement
- IONS valuation and score
- PCRX stock overview
- PCRX income statement
- PCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.